OVERVIEW OF ACTIVITY
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancers. It is estimated that 24,050 new cases will be diagnosed and 11,090 deaths will occur in the United States in 2014. In recent years extensive research has led to the introduction of new agents with substantial activity that have improved outcomes and allowed patients to experience longer periods of remission. Both novel proteasome inhibitors and immunomodulatory agents have effectively transformed the standard treatment for patients with MM. Controversies still persist, however, in several areas of patient care, such as selection of the optimal induction therapy for transplant and nontransplant candidates and post-transplant maintenance strategies. The current challenge facing the oncology community is identifying those patients who will obtain the greatest benefit from a specific regimen while incurring the least toxicity.

To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in the treatment of MM to assist medical oncologists, hematologists, hematologist-oncologists, hematology-oncology fellows and other cancer clinicians in the formulation of up-to-date and appropriate treatment strategies.

LEARNING OBJECTIVES

• Consider the decision-making of clinical investigators with expertise in the management of MM, and use this information to potentially alter future selection of induction and maintenance regimens for transplant-eligible patients with this disease.
• Assess the optimal duration of induction and maintenance therapies for transplant-eligible patients with MM.
• Evaluate the impact of patient risk status and level of response on faculty preferences for post-transplant maintenance therapy for patients with MM.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This activity consists of a text component. The participant should review the treatment preference matrices.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Andrzej J Jakubowiak, MD, PhD
Director, Myeloma Program
Professor, Department of Medicine
Section of Hematology/Oncology
University of Chicago Medical Center
Chicago, Illinois

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi, Skyline Pharmaceuticals Inc; Consulting Agreements and Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary.

Ola Landgren, MD, PhD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary.

Philip L McCarthy, MD
Professor of Oncology and Internal Medicine
BMT Program
Roswell Park Cancer Institute and State University of New York at Buffalo
Buffalo, New York

Advisory Committee: Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi.

Joseph Mikhael, MD, MEd
Associate Dean, Mayo School of Graduate Medical Education
Deputy Director - Education, Mayo Clinic Cancer Center
Associate Professor, Mayo College of Medicine
Mayo Clinic in Arizona
Scottsdale, Arizona

Contracted Research: Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.

Philippe Moreau, MD
Professor of Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.

Antonio Palumbo, MD
Chief, Myeloma Unit
Division of Hematology
University of Torino
Torino, Italy

Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Sanofi.

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center 
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals, an Amgen subsidiary.

Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation and Onyx Pharmaceuticals, an Amgen subsidiary.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: December 2014
Expiration date: December 2015